A Phase 1-2, Double-Blind, Sham-Controlled Multiple Ascending Dose Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Patients With MECP2 Duplication Syndrome
Latest Information Update: 05 Jul 2025
At a glance
- Drugs ION 440 (Primary)
- Indications Lubs X-linked mental retardation syndrome
- Focus Adverse reactions
- Acronyms ATTUNE
- Sponsors Ionis Pharmaceuticals
Most Recent Events
- 05 Jul 2025 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 22 Oct 2024 Status changed from not yet recruiting to recruiting.
- 19 Sep 2024 Planned initiation date changed from 1 Aug 2024 to 1 Oct 2024.